Oncolytics Biotech Begins New Study for Advanced Pancreatic Cancer Treatment
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech Inc. (NASDAQ:ONCY) has initiated a new study cohort for advanced pancreatic cancer treatment, evaluating pelareorep and modified FOLFIRINOX with or without atezolizumab. The study is supported by a $5M PanCAN Therapeutic Accelerator Award and will focus on objective response rate and safety.
June 20, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech Inc. has started a new study cohort for advanced pancreatic cancer treatment, which could potentially lead to new treatment options and revenue streams. The study is supported by a $5M PanCAN award.
The initiation of a new study cohort for advanced pancreatic cancer treatment by Oncolytics Biotech is a significant development. The support from a $5M PanCAN award adds credibility and financial backing, which could lead to positive investor sentiment and potential revenue growth if the study yields successful results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100